Non-invasive allergen-specific immunotherapy for respiratory and gastrointestinal allergies
Innovative non-invasive immunotherapy platform using transdermal and mucosal delivery for respiratory and gastrointestinal allergies. Demonstrated effectiveness in animal models with significant IgE reduction and enhanced allergen penetration. Future clinical trials planned.
Overview
This non-invasive immunotherapy platform offers a revolutionary approach to treating respiratory and gastrointestinal allergies. By leveraging advanced transdermal and mucosal delivery systems, it ensures efficient allergen penetration without the invasiveness of traditional methods. The technology has shown promising results, achieving a 94% reduction in IgE levels in animal models, comparable to subcutaneous therapy. It also utilizes a proprietary iontophoresis and ionic liquid technology, enhancing intradermal delivery by 3 to 5 times compared to existing solutions like Viaskin®.
Technical specifications
The platform integrates multiple innovative technologies:
- Allergen Extraction Technology: Produces potent allergen solutions with a concentration of 1.15 μg/mL and minimal batch variability (<12.6%).
- Transdermal/Mucosal Delivery: Utilizes thermosensitive, microneedle, and iontophoresis methods to improve penetration and efficacy.
- Adhesion and Retention: Features a breakthrough adhesion system with patch adhesion exceeding 0.5 N/cm and mucosal retention over 8 hours.
- Smart Delivery System: Achieves transdermal efficiency of 40% with a release profile deviation of less than 5%.
- Validated in Various Models: Proven in animal models for allergic rhinitis, asthma, and food allergies.
Technology readiness level
The technology is currently at TRL 5, having progressed beyond conceptualization to integration and validation. Future plans include optimizing materials for sustained release, expanding the platform to other allergens like pollen and pet dander, and generating IND-enabling safety and efficacy data for clinical trials.
About China Pharmaceutical University
China Pharmaceutical University (CPU) is a specialized public research university in Nanjing, directly under the Ministry of Education and part of China’s Double First-Class initiative, with a large student body and a pharmacy-centered profile. CPU connects with industry through formal university–enterprise collaboration platforms and practice bases, including co-developed training and applied R&D with leading pharmaceutical companies. Its position within Nanjing and the broader Yangtze River Delta places partners near a fast-growing biopharma cluster and dedicated industrial parks that support innovation and commercialization. Research is backed by competitive national funding from the National Natural Science Foundation of China and ministry-level programs, with faculty frequently leading NSFC-supported projects. A dedicated technology transfer center manages IP, licensing, and industry contracts to streamline commercialization.
delivered to your inbox.